Zacks Research Has Negative Outlook for ESPR FY2027 Earnings

Key Points

• Investment analysts at Zacks Research have reduced their FY2027 earnings per share estimate for Esperion Therapeutics from $0.06 to $0.05, while the current consensus estimate for the year is a loss of $0.29 per share.
• Esperion Therapeutics reported a quarterly earnings per share of ($0.21), missing expectations, but achieved revenue of $65 million, surpassing analyst projections of $54.97 million.
• The stock ratings for Esperion Therapeutics vary, with two analysts giving it a hold rating and four assigning a buy rating, resulting in a consensus rating of "Moderate Buy" and a price target of $7.00.

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at Zacks Research cut their FY2027 EPS estimates for Esperion Therapeutics in a research note issued to investors on Monday, July 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn $0.05 per share for the year, down from their previous forecast of $0.06. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share.

A number of other analysts have also issued reports on the stock. Needham & Company LLC reduced their price target on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group lowered their price target on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Finally, HC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday, June 17th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $7.00.

Esperion Therapeutics Trading Down 1.4%

ESPR stock traded down $0.02 during mid-day trading on Tuesday, reaching $1.40. 2,627,163 shares of the stock traded hands, compared to its average volume of 4,732,040. Esperion Therapeutics has a 52-week low of $0.69 and a 52-week high of $3.94. The company has a market cap of $277.48 million, a P/E ratio of -1.75 and a beta of 0.70. The stock's fifty day moving average is $1.14 and its 200-day moving average is $1.35.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). Esperion Therapeutics had a negative net margin of 59.03% and a negative return on equity of 0.91%. The firm had revenue of $65.00 million for the quarter, compared to analysts' expectations of $54.97 million.

Institutional Investors Weigh In On Esperion Therapeutics

Several institutional investors have recently modified their holdings of the business. Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics in the 2nd quarter valued at approximately $25,000. North Star Investment Management Corp. bought a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $25,000. Meridian Wealth Management LLC bought a new stake in shares of Esperion Therapeutics during the 1st quarter worth approximately $29,000. Synergy Asset Management LLC raised its stake in shares of Esperion Therapeutics by 3,496.3% during the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 30,138 shares in the last quarter. Finally, Boomfish Wealth Group LLC raised its stake in shares of Esperion Therapeutics by 29.5% during the 2nd quarter. Boomfish Wealth Group LLC now owns 45,306 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 10,309 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.